OBJECTIVE： To investigate the effects of different doses of tanshinone ⅡA on hemodynamics in patients underwent non-extracorporeal circulation coronary artery bypass grafting （NECCABG）. METHODS： A total of 66 patients underwent selective NECCABG during Nov. 2016-Apr. 2017 were selected and divided into control group （33 cases） and observation group （33 cases） according to random number tablet. Both groups were given Tanshinone ⅡA sodium sulfonate injection with loading dose of 0.4  μg/kg for 10 min at the beginning of surgery. Control group was given Tanshinone ⅡA sodium sulfonate injection 0.2 μg/（kg·h）continuously till the end of surgery； observation group was given 0.4 μg/（kg·h） continuously till the end of surgery. HR， MAP， central venous pressure （CVP）， mean pulmonary arterial pressure （MPAP）， pulmonary capillary wedge pressure （PCWP）， cardiac index （CI）， systemic vascular resistance index （SVRI）， pulmonary circulation resistance index （PVRI） and the occurrence of ADR were observed in 2 groups before anesthesia induction （T0）， 5 min after tracheal intubation （T1）， at the moment of sternum cut （T2）， at the end of anastomosis of anterior descending branch （T3）， at the end of anastomosis of right coronary artery （T4）， at the end of operation （T5）. RESULTS： At T0， there was no statistical significance in HR， MAP， CVP， MPAP， PCWP， CI， SVRI or PVRI between 2 groups （P＞0.05）. At T1-T5， HR， MAP， CVP， MPAP， PCWP， SVRI and PVRI of control group were significantly higher than at T0， with statistical significance （P＜0.05）. There was no statistical significance in CI of control group among at T1-T5 and with at T0； there was no statistical significance in HR， MAP， CVP， MPAP， PCWP， SVRI or PVRI of observation group between at T1-T5 with at T0 （P＞0.05）. At T1-T5， CI of observation group was significantly higher than at T0 and than control group； HR， MAP， CVP， MPAP， PCWP， SVRI and PVRI were significantly lower than control group， with statistical significance （P＜0.05）. No obvious ADR was found in 2 groups during medication. CONCLUSIONS： Tanshinone ⅡA 0.4 μg/（kg·h） is helpful to keep hemodynamics stable and improve heart function in patients with NECCABG with good safety.